VertiFlex Completes Superion Interspinous Trial Enrollment

VertiFlex, a San Clemente, Calif.-based spine device company, has completed enrollment for its IDE clinical trail for the Superion Interspinous Spacer, according to a company news release.

Advertisement

The study was a multi-center, controlled trial examining the safety and efficacy of the Superion ISS compared to the X-Stop IPD. The system is designed to perform a minimally invasive surgical technique.

Related Articles on Spine Surgery:

Minimally Invasive TLIF Has Economic Benefits Over Open Surgery

Study Analyzes Impact of Growing Rod Lengthening Surgery Overtime

Now is a Great Time to be a Physician: Q&A With Dr. John Caruso on Physician Involvement in Healthcare Changes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.